Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling

BMC Infectious Diseases

Andreas M Kaufmann²  Ole Wichmann¹  Achim Schneider²  Michaela Fesenfeld¹  Melanie Schuster¹  Josefine Leuschner²  Cornelius Remschmidt¹  Yvonne Deleré¹ 

[1] Immunisation Unit, Department for Infectious Disease Epidemiology, Robert Koch Institute, Seestraße 10 13353 Berlin, Germany;Clinic for Gynaecology, Charité - Universitaetsmedizin Berlin, Berlin, Germany

关键词: Epidemiology;    Self-sampling;    Genotype distribution;    Cervical cancer;    HPV;   

Others  :  1134650
DOI  :  10.1186/1471-2334-14-87

 received in 2013-09-14, accepted in 2014-02-10,  发布年份 2014

【 摘 要 】

Background

Estimates of Human Papillomavirus (HPV) prevalence in a population prior to and after HPV vaccine introduction are essential to evaluate the short-term impact of vaccination.

Methods

Between 2010 and 2012 we conducted a population-based cross-sectional study in Germany to determine HPV prevalence, genotype distribution and risk factors for HPV-infection in women aged 20-25 years. Women were recruited by a two-step cluster sampling approach. A home-based self-collection of cervicovaginal lavages was used. Specimens were analysed using a general primer GP5+/GP6+-based polymerase chain reaction and genotyped for 18 high-risk and 6 low-risk HPV- strains by Luminex-based multiplexed genotyping.

Results

Among 787 included women, 512 were not vaccinated against HPV. In the non-vaccinated population, HPV prevalence of any type was 38.1%, with HPV 16 (19.5%) being the most prevalent genotype. Prevalence of any high-risk type was 34.4%, and in 17.4% of all women, more than one genotype was identified. A higher number of lifetime sexual partners and low educational status were independently associated with HPV-infection. In 223 vaccinated women, prevalence of HPV 16/18 was significantly lower compared to non-vaccinated women (13.9% vs. 22.5%, p = 0.007). When stratifying by age groups, this difference was only significant in women aged 20-21 years, who at time of vaccination were on average younger and had less previous sexual contacts than women aged 22-25 years.

Conclusion

We demonstrate a high prevalence of high-risk HPV genotypes in non-vaccinated women living in Germany that can be potentially prevented by vaccination. Probable first vaccination effects on the HPV prevalence were observed in women who were vaccinated at younger age. This finding reinforces the recommendation to vaccinate girls in early adolescence.

【 授权许可】

   
2014 Deleré et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, O'Flanagan D, Lopalco PL, D'Ancona F, Levy-Bruhl D, et al.: The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010, 15:47.
• [2]Delere Y, Meyer C, Reiter S: Universal immunisation with human papillomavirus (HPV) vaccine among females aged 12-17 recommended in Germany. Euro Surveill 2007, 12(4):E070405 070402.
• [3]Scheidt-Nave C, Kamtsiuris P, Gosswald A, Holling H, Lange M, Busch MA, Dahm S, Dolle R, Ellert U, Fuchs J, et al.: German health interview and examination survey for adults (DEGS) - design, objectives and implementation of the first data collection wave. BMC Public health 2012, 12:730. BioMed Central Full Text
• [4]Regionen BIK: Ballungsräume, Stadtregionen, Mittel-/Unterzentrengebiete. Methodenbeschreibung zur Aktualisierung 2000. Hamburg:  ; 2001. [ http://www.bik-gmbh.de/texte/BIK-Regionen2000.pdf webcite]
• [5]Cox LH: A constructive procedure for unbiased controlled rounding. J Am Stat Assoc 1987, 82:520-524.
• [6][Genesis Online Database]: Federal statistical office, Wiesbaden. No author.    . Available from: https://www-genesis.destatis.de/genesis/online webcite. Accessed on 18 April 2013
• [7]Robert Koch Institute: Data and facts: results of the study "health in Germany in 2010". In  . Berlin (Germany): Robert Koch Institute; 2012. Available at http://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsB/GEDA2010.pdf?__blob=publicationFile webcite. Accessed on 18 April 2013
• [8]Delere Y, Schuster M, Vartazarowa E, Hansel T, Hagemann I, Borchardt S, Perlitz H, Schneider A, Reiter S, Kaufmann AM: Cervicovaginal self-sampling is a reliable method for determination of prevalence of human papillomavirus genotypes in women aged 20 to 30 years. J Clin Microbiol 2011, 49(10):3519-3522.
• [9]Schmitt M, Dondog B, Waterboer T, Pawlita M: Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 2008, 46(3):1050-1059.
• [10]Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T: Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008, 123(8):1864-1870.
• [11]Schwabe U, Paffrath D: Arzneiverordnungsreport 2009. In  . Berlin Heidelberg: Springer; 2010.
• [12]Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE: Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006. J Infect Dis 2011, 204(4):566-573.
• [13]Iftner T, Eberle S, Iftner A, Holz B, Banik N, Quint W, Straube AN: Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study. J Med Virol 2010, 82(11):1928-1939.
• [14]Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Reinecke-Luthge A, Grunwald E, Schulze-Rath R, Iftner T: Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis 2013, 13:135. BioMed Central Full Text
• [15]Ruckinger S, Tauscher M, Redel R, Munte A, Walchner-Bonjean M, Hess J, Schneider A, von Kries R: Participation in cervical cancer screening by age and region–a cohort study with a 3 1/2 year follow-up on 2,223,135 women in Bavaria. Gesundheitswesen 2008, 70(6):e17-e21.
• [16]Carozzi FM, Del Mistro A, Confortini M, Sani C, Puliti D, Trevisan R, De Marco L, Tos AG, Girlando S, Palma PD, et al.: Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. Am J Clin Pathol 2005, 124(5):716-721.
• [17]Comar M, Iannacone MR, Casalicchio G, McKay-Chopin S, Tommasino M, Gheit T: Comparison of hybrid capture II, linear array, and a bead-based multiplex genotyping assay for detection of human papillomavirus in women with negative pap test results and atypical squamous cells of undetermined significance. J Clin Microbiol 2012, 50(12):4041-4046.
• [18]Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE: Prevalence of HPV infection among females in the United States. JAMA 2007, 297(8):813-819.
• [19]Jensen KE, Munk C, Sparen P, Tryggvadottir L, Liaw KL, Dasbach E, Nygard M, Kjaer SK: Women's sexual behavior. Population-based study among 65,000 women from four Nordic countries before introduction of human papillomavirus vaccination. Acta obstetricia et gynecologica Scandinavica 2011, 90(5):459-467.
• [20]Langille DB, Asbridge M, Flowerdew G, Allen M: Associations of sexual risk-taking with having intercourse before 15 years in adolescent females in Cape Breton, Nova Scotia, Canada. Sexual Health 2010, 7(2):199-204.
• [21]Remschmidt C, Kaufmann AM, Hagemann I, Vartazarova E, Wichmann O, Delere Y: Risk factors for cervical human papillomavirus infection and high-grade intraepithelial lesion in women aged 20 to 31 years in Germany. Int J Gynecol Cancer 2013, 23(3):519-526.
• [22]Kjaer SK, Dahl C, Engholm G, Bock JE, Lynge E, Jensen OM: Case-control study of risk factors for cervical neoplasia in Denmark. II. Role of sexual activity, reproductive factors, and venereal infections. Cancer Causes and Control 1992, 3(4):339-348.
• [23]Nordenvall C, Chang ET, Adami HO, Ye W: Cancer risk among patients with condylomata acuminata. Int J Cancer 2006, 119(4):888-893.
• [24]Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK: Genital warts and risk of cancer: a Danish study of nearly 50 000 patients with genital warts. J Infect Dis 2012, 205(10):1544-1553.
• [25]Nielsen A, Kjaer SK, Munk C, Iftner T: Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis 2008, 35(3):276-282.
• [26]Carcopino X, Henry M, Mancini J, Giusiano S, Boubli L, Olive D, Tamalet C: Significance of HPV 16 and 18 viral load quantitation in women referred for colposcopy. J Med Virol 2012, 84(2):306-313.
• [27]Tamalet C, Le Retraite L, Leandri FX, Heid P, Sancho Garnier H, Piana L: Vaginal self-sampling is an adequate means of screening HR-HPV types in women not participating in regular cervical cancer screening. Clin Microbiol Infect 2013, 19(1):E44-E50.
• [28]Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER: Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013, 208(3):385-393.
• [29]Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Cummins E, Liu B, Bateson D, McNamee K, Garefalakis M, Garland SM: Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206(11):1645-1651.
• [30]Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR, Porras C, Schussler J, Jimenez S, Sherman ME, et al.: Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discovery 2011, 1(5):408-419.
• [31]Rolnick SJ, Parker ED, Nordin JD, Hedblom BD, Wei F, Kerby T, Jackson JM, Crain AL, Euler G: Self-report compared to electronic medical record across eight adult vaccines: do results vary by demographic factors? Vaccine 2013, 31(37):3928-3935.